With these robust findings, CagriSema has the potential to be the first amylin and GLP-1 combination therapy that addresses blood glucose control with reductions in bodyweight for people living with type 2 diabetes." Amylin, a pancreatic hormone co-secreted with insulin in response to food intake, plays a distinct yet complementary role to GLP-1, with potential roles in appetite, glycemic control, bone metabolism, and bodyweight
Results vary between individuals
Because spicy foods are famous for their metabolic-boosting properties, it is natural to ask if they are friends or foes to this delicate endocrine organ
Topical failures don't necessarily predict injectable failures, and vice versa
The D,L-form does not help the body use fat and can actually interfere with and cause a lack of levocarnitine
Follicles in the treatment group grew measurably longer than untreated follicles over the same 12-day period